Literature DB >> 19601871

Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.

Yan Chang1, David E Moody.   

Abstract

We investigated the enzyme kinetics of buprenorphine and norbuprenorphine glucuronidation in human liver microsomes and UDP-glucuronosyltransferase (UGT) Supersomes. The involvement of UGT 1A1, 1A3 and 2B7 in buprenorpine and 1A3 in norbuprenorphine glucuronidation were confirmed. Novel involvement of 2B17 with buprenorphine and 1A1 with norbuprenorphine were demonstrated. Scaling of buprenorphine clearance with, or without, correction for the nonspecific microsomal protein binding of buprenorphine (f(u) = 0.42) suggested glucuronidation was a significant route for hepatic clearance of buprenorphine.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19601871     DOI： 10.2174/187231209788654117

Source DB:  PubMed          Journal:  Drug Metab Lett        ISSN： 1872-3128


  23 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

2.  An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation.

Authors:  Stephanie Oechsler; Gisela Skopp
Journal:  Int J Legal Med       Date:  2010-01-29       Impact factor: 2.686

3.  Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.

Authors:  Ellen G J Hulskotte; R Douglas Bruce; Hwa-Ping Feng; Lynn R Webster; Feng Xuan; Wen H Lin; Edward O'Mara; John A Wagner; Joan R Butterton
Journal:  Eur J Clin Pharmacol       Date:  2015-02-11       Impact factor: 2.953

Review 4.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

5.  Transdermal buprenorphine-interesting observations on the metabolite norbuprenorphine levels in elderly subjects.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

6.  No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.

Authors:  Matthew P Kosloski; Weihan Zhao; Armen Asatryan; Jens Kort; Pierre Geoffroy; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

7.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

8.  Analgesia during Monkeypox Virus Experimental Challenge Studies in Prairie Dogs (Cynomys ludovicianus).

Authors:  Christina L Hutson; Nadia Gallardo-Romero; Darin S Carroll; Johanna S Salzer; Jessica D Ayers; Jeff B Doty; Christine M Hughes; Yoshi Nakazawa; Paul Hudson; Nishi Patel; M S Keckler; Victoria A Olson; Tamas Nagy
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-05-29       Impact factor: 1.232

Review 9.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

10.  Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Authors:  T Garimella; R Wang; W-L Luo; P Wastall; H Kandoussi; M DeMicco; R D Bruce; C Hwang; R Bertz; M Bifano
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.